<DOC>
	<DOCNO>NCT00881621</DOCNO>
	<brief_summary>Patients ask participate study locally advance metastatic pancreatic cancer ( cancer pancreas spread another part body ) get bad first-line chemotherapy . The purpose study see drug , Capecitabine Lapatinib ( two chemotherapy agent ) , prolong survival improve quality life compare supportive care alone . Lapatinib combination drug call capecitabine , approve Food Drug Administration ( FDA ) treatment metastatic breast cancer . It yet approve treat type cancer . Both drug pill . This research do know combination Capecitabine Lapatinib well supportive care alone pancreatic cancer .</brief_summary>
	<brief_title>Lapatinib Capecitabine Second Line Treatment Pancreas Cancer</brief_title>
	<detailed_description>This open-label single-arm Phase II trial patient metastatic pancreatic cancer fail first line Gemcitabine-based therapy . Patients treated combination Capecitabine Lapatinib , dual tyrosine-kinase inhibitor EGFR HER-2 .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histologically confirm adenocarcinoma pancreas Prior fail 1st line gemcitabine therapy metastatic disease relapse within six month completion gemcitabine adjuvant therapy Prior capecitabine 5fu allow set radiation Must either able swallow receive enteral nutrition via gastrostomy feed tube Cardiac ejection fraction within institutional range normal measure echocardiogram ECOG performance status 02 Signed inform consent form Adequate hepatic , bone marrow , renal function Any prior treatment lapatinib , antiHER2 treatment antiEGFR treatment Not recovered adverse event toxicity grade &lt; /= 1 due prior chemotherapy More one prior chemotherapy regimen Known brain metastasis , uncontrolled seizure disorder , encephalitis , multiple sclerosis HIV positive antiretroviral therapy Pregnant lactate History allergic reaction attribute compound similar chemical biologic composition lapatinib capecitabine Malabsorption syndrome uncontrolled inflammatory GI disease ( Crohn 's ulcerative colitis ) Known history uncontrolled symptomatic angina , arrhythmia , congestive heart failure Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/ social situation would limit compliance study requirement Known dihydropyrimidine dehydrogenase deficiency Concurrent malignancy unless subject curatively treated disease free &gt; /= 2 year cancer nonmelanoma skin cancer early cervical cancer . Creatinine clearance &lt; 30 mL/min Absolute neutrophil count &lt; 1500 , platelets &lt; 75,000 Transaminases &gt; 3.0 time upper limit normal , except know hepatic metastasis , wherein must &lt; 5.0 time upper limit normal Total bilirubin &gt; 1.5 time ULN , &gt; 2.5 x ULN patient Gilbert 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreas cancer</keyword>
	<keyword>lapatinib</keyword>
	<keyword>capecitabine</keyword>
</DOC>